The proceeds will be used to accelerate the pre-clinical R&D of its anti-viral nanobody drugs.
Banke Biology (Chinese: 班科生物) recently announced its completion of the Angel round of financing worth over tens of millions of CNY.
This round was led by Donghu Capital(Chineses: 东湖投资) with participation from Baiying Investment (Chinese: 百赢投资). The proceeds will be used for its pre-clinical research of anti-viral nanobody drugs, the advancement of R&D of other product pipelines and the team building.
Founded in July 2011, Banke Bio is dedicated to R&D of novel antibody drugs and has established a complete and multi-dimensional platform for antibody drug R&D. The proprietary next-generation nanobody technology platform owned by Banke can be deployed for the structure design, modification, high-throughput screening and drug development of nanobody.
Banke Bio’s competitors include Novamab (Chinese: 洛启生物), NB Biolab and Icare Antibody (Chinese: 爱康得生物).